breast
cancer
bc
repres
common
malign
second
lead
caus
cancer
relateddeath
worldwid
almost
twothird
bc
estrogen
receptorposit
er
human
epiderm
growth
factor
receptor
er
bc
offer
excit
advanc
develop
inhibitor
palbociclib
ribociclib
abemaciclib
lead
major
shift
treatment
landscap
combin
endocrin
therapi
inhibitor
consid
mainstay
treatment
preand
postmenopaus
patient
metastat
er
bc
neutropenia
common
grade
advers
event
observ
clinic
trial
involv
inhibitor
frequenc
respect
paloma
paloma
guidelin
publish
manag
advers
event
dose
reduct
case
isol
lymphopenia
without
concomit
opportunist
infect
specif
monitor
dose
reduct
current
recommend
femal
receiv
inhibitor
palbociclib
combin
exemestan
metastat
er
breast
cancer
admit
emerg
depart
acut
dyspnea
set
sever
cellular
immunodefici
metastat
relaps
occur
patient
receiv
firstlin
chemotherapi
taxaneschemotherapi
combin
bevacizumab
consecut
hormon
therapi
februari
januari
symptomat
periton
tumor
progress
occur
januari
palbociclib
mg
per
day
administ
oral
cycl
week
treatment
follow
week
concomitantli
exemestan
mg
per
day
may
intestin
obstruct
occur
result
periton
diseas
comput
tomographi
ct
scan
cancer
antigen
stabl
argument
progress
diseas
corticosteroid
therapi
prednisolon
start
may
result
manag
intercurr
event
grade
neutropenia
also
report
accord
palbociclibinduc
neutropenia
manag
guidelin
dosag
palbociclib
adjust
mg
mg
per
day
without
diseas
progress
juli
ct
scan
august
patient
admit
emerg
depart
hypercalcemia
fever
deterior
gener
statu
patient
treat
intraven
bisphosphon
hypercalcemia
diagnos
obstruct
pyelonephr
result
doubl
jcathet
impair
bacteriolog
investig
show
colon
enterococcu
faecali
klebsiella
oxytoca
lead
betalactam
antibiot
piperacillin
tazobactam
day
togeth
ureter
stent
replac
patient
remain
persist
febril
acut
respiratori
symptom
cough
phlegm
dyspnea
urin
antigen
test
although
rare
outcom
palbociclib
induc
sever
lymphopenia
sever
cellular
immunodefici
lead
lifethreaten
opportunist
infect
strongli
recommend
close
monitor
lymphocyt
patient
receiv
palbociclib
primari
pneumocysti
prevent
lymphopenia
count
less
lymphocyt
less
diagnosi
respiratori
infect
name
legionellosi
pneumococc
pneumonia
neg
well
blood
cultur
report
chest
xray
ct
scan
perform
show
acut
diffus
interstiti
pneumonia
figur
basi
noninvas
bronchial
wash
cytolog
lung
lesion
bacteri
viral
infect
includ
polymeras
chain
reaction
pcr
assay
influenza
viru
coronaviru
rhinoviru
enteroviru
metapneumoviru
bocaviru
adenoviru
parainfluenza
viru
exclud
interestingli
pneumocystisspecif
pcr
posit
well
detect
fungal
bdglucan
antigen
anoth
commonli
encount
fungal
agent
aspergillu
niger
detect
reactiv
multipl
latent
virus
document
pcr
herp
simplex
viru
epsteinbarr
viru
cytomegaloviru
well
viral
cytomegaloviru
level
mildli
elev
bronchial
wash
fluid
plasma
respect
associ
result
grade
lymphopenia
observ
close
observ
found
decreas
lymphocyt
count
time
follow
gl
januari
gl
februari
gl
april
less
gl
may
figur
immunophenotyp
peripher
tlymphocyt
record
reduct
absolut
number
cell
less
consist
palbociclibinduc
bone
marrow
suppress
note
patient
human
immunodefici
viru
test
neg
patient
start
highdos
sulfamethoxazol
trimethoprim
smxtmp
equival
tmp
mgkgday
smx
mgkgday
plu
highdos
steroid
therapi
prednison
mgkg
equival
per
day
improv
infect
respiratori
deterior
treatment
failur
pneumocysti
pneumonia
sever
deterior
gener
statu
agreement
patient
best
support
care
initi
death
record
day
later
pneumocysti
pneumonia
lifethreaten
opportunist
pulmonari
fungal
infect
among
immunocompromis
patient
import
factor
adjunct
steroid
immunomodulatori
agent
addit
uncontrol
breast
cancer
may
underli
immunodefici
disord
nonhuman
immunodefici
virusinfect
patient
result
treatmentrel
grade
iii
lymphopenia
lymphocyt
rang
gl
diagnos
may
concomit
palbociclib
exemestan
treatment
prednisolon
initi
may
dose
mgday
given
day
taper
dose
mgday
longterm
case
causal
assess
pneumocysti
pneumonia
palbociclib
support
tempor
progress
leucopenia
associ
unexpect
lymphopenia
worsen
palbociclib
cours
final
associ
opportunist
infect
patient
risk
factor
infecti
complic
coprescript
corticosteroid
could
affect
suscept
opportunist
infect
report
case
fatal
pneumocysti
pneumonia
involv
femal
metastat
er
bc
receiv
palbociclib
mg
per
day
concomitantli
exemestan
mg
per
day
patient
experienc
decreas
lymphocyt
count
time
gl
januari
time
palbociclibexemestan
initi
less
gl
may
sever
cellular
immunodefici
led
reactiv
multipl
latent
virus
occurr
pneumocysti
pneumonia
believ
grade
lymphopenia
could
trigger
inhibitor
palbociclib
gener
analysi
cyclin
mice
show
cyclin
anim
fail
undergo
normal
expans
immatur
lymphocyt
absenc
cyclin
normal
assembl
pretcr
fail
drive
expans
immatur
thymocyt
cofactor
cyclin
requir
expans
thu
inhibitor
impair
lead
sever
lymphopenia
could
observ
phase
ii
paloma
clinic
trial
respect
grade
lymphopenia
surprisingli
grade
lymphopenia
document
phase
iii
paloma
clinic
trial
present
patient
experienc
sever
fatal
immunodefici
character
extend
grade
lymphopenia
accord
common
terminolog
criteria
advers
event
concomit
palbociclib
exemestan
administr
led
reactiv
viral
infect
herp
simplex
viru
varicellazost
viru
aleut
diseas
viru
epsteinbarr
viru
occurr
pneumocysti
pneumonia
accord
pharmacovigil
depart
similar
case
found
bibliograph
sourc
product
inform
martindal
pubm
therefor
lymphopenia
opportunist
infect
consid
unexpect
advers
effect
palbociclib
pharmacovigil
unit
run
vigibas
world
health
organ
global
databas
individu
case
safeti
report
septemb
contain
report
multipl
sourc
countri
report
strength
causal
variabl
nevertheless
found
case
lymphopenia
associ
palbociclib
case
part
observ
studi
infect
associ
remain
case
spontan
report
europ
n
north
america
n
case
lymphopenia
associ
herp
zoster
infect
case
influenza
shown
lymphopenia
could
owe
inhibitor
palbociclib
fact
argument
bone
marrow
involv
leukocyt
platelet
count
normal
grade
anemia
observ
probabl
induc
multifactori
caus
includ
palbociclib
toxic
sepsi
vitamin
defici
inflamm
moreov
lymphopenia
occur
soon
april
long
sepsi
mention
exemestan
induc
mild
lymphopenia
lymphocyt
count
remain
stabl
time
grade
lymphopenia
report
coprescript
includ
lansoprazol
prednisolon
nefopam
paracetamol
levothyroxin
denosumab
none
treatment
known
induc
lymphopenia
prednisolon
dose
mgday
may
contribut
opportunist
pulmonari
fungal
infect
immunosuppress
properti
although
manag
palbociclibinduc
neutropenia
welldocu
manag
palbociclibinduc
lymphopenia
undefin
close
monitor
dose
adapt
requir
opportunist
infect
appear
clinic
breast
cancer
april
shown
lymphocyt
count
care
monitor
sever
lymphopenia
lymphocyt
count
ae
lymphocyt
could
result
prescript
primari
pneumocystosi
prevent
like
acquir
immunodefici
syndrom
organtranspl
patient
recommend
special
attent
given
patient
receiv
corticosteroid
prednison
mg
equival
month
common
situat
solid
oncolog
manag
symptom
relat
progress
diseas
periton
carcinosi
pain
lymphang
etc
mention
drug
interact
observ
smxtmp
palbociclib
palbociclib
metabol
wherea
smx
tmp
select
inhibitor
coadministr
drug
appear
safe
observ
phase
iii
paloma
clinic
trial
inhibitor
palbociclib
induc
sever
lymphopenia
sever
cellular
immunodefici
character
low
lymphocyt
count
lead
opportunist
infect
primari
pneumocysti
pneumonia
prevent
systemat
discuss
patient
lymphopenia
count
cellular
immunodefici
induc
palbociclib
clinic
breast
cancer
april
less
lymphocyt
less
discuss
patient
receiv
corticosteroid
includ
prednisolon
mg
equival
month
strongli
recommend
close
monitor
lymphocyt
patient
receiv
palbociclib
author
state
conflict
interest
